Elevance Health Inc. reported fourth‑quarter 2025 results that included a $49.3 billion revenue figure, 10% higher year‑over‑year, but the figure fell short of the consensus estimate of roughly $49.8 billion. Adjusted earnings per share came in at $3.33, beating the consensus of $3.10 by $0.23, or 7.4%. The company’s benefit expense ratio climbed to 93.5%, reflecting higher medical costs in its ACA and Medicaid businesses, while operating revenue grew 10% to $49.3 billion.
The revenue growth was driven largely by the Carelon Services segment, which added 27% to operating revenue, offsetting headwinds in the Health Benefits and CarelonRx segments. The higher benefit expense ratio indicates that medical cost inflation is outpacing premium growth, a trend that has pressured margins across the industry. Despite the revenue miss, the company’s pricing discipline and cost‑control initiatives helped it maintain a positive adjusted EPS beat.
Operating results for the quarter were more mixed. The company posted an adjusted operating loss of $0.2 billion, a reversal from the $0.3 billion gain reported in the original article. The adjusted operating margin fell to 0.8% from 1.9% in the prior year, reflecting the combined impact of higher benefit costs and a shift in the mix toward lower‑margin ACA and Medicaid business. The full‑year adjusted operating margin for 2025 was 2.5%, a decline from 3.8% in 2024, underscoring the ongoing margin compression the company faces.
Guidance for fiscal 2026 is cautious. Elevance Health reiterated a full‑year adjusted EPS range of at least $25.50, below the Wall Street estimate of $26.90. The company also forecast a benefit expense ratio of 90.2% and an adjusted operating expense ratio of 10.6%. Management explained that the guidance reflects a projected decline in premium revenue, a continued rise in medical costs, and the impact of non‑recurring favorable items that boosted 2025 EPS by roughly $3.75 per share. The company’s outlook signals confidence in returning to at least 12% adjusted EPS growth in 2027, but it also highlights the near‑term challenges of a low‑single‑digit revenue decline and margin pressure.
CEO Gail Boudreaux emphasized that 2026 will be a year of “execution and repositioning.” She highlighted the company’s focus on improving affordability, scaling solutions, and leveraging artificial intelligence to enhance member experience. Boudreaux also noted that the company is investing in targeted initiatives to strengthen its earnings power across its diversified platform, while maintaining disciplined pricing and cost management. The guidance and commentary suggest that Elevance Health is prioritizing long‑term resilience over short‑term growth, a strategy that may appeal to investors seeking stability in a high‑cost environment.
Investors reacted cautiously to the earnings release. While the EPS beat was welcomed, the revenue miss and the lower 2026 guidance tempered enthusiasm. Analysts noted that the company’s 2025 EPS was inflated by non‑recurring items, making the 2026 outlook appear more modest. The market’s focus on the guidance and the underlying cost pressures indicates that investors are weighing the company’s ability to navigate a challenging healthcare environment while maintaining profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.